0000000000911496

AUTHOR

Nicolas Delarche

showing 3 related works from this author

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct

9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System

2016

Abstract Objectives The aim of this study was to assess the safety and effectiveness of the COBRA Polyzene-F NanoCoated Coronary Stent System (CeloNova Biosciences, San Antonio, Texas) for the treatment of de novo coronary artery lesions. Background Polyzene-F–coated coronary stents have shown reduced thrombogenicity and inflammation in preclinical studies. Methods Patients with de novo coronary artery lesions meeting eligibility criteria were enrolled in a nonrandomized, prospective clinical trial. The primary endpoint was target vessel failure (TVF) (defined as a composite of cardiac death, myocardial infarction, or clinically driven target vessel revascularization) at 9 months. A pre-spe…

Malemedicine.medical_specialtyTime FactorsPolymersmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyProsthesis DesignCoronary RestenosisCoronary artery disease03 medical and health sciencesOrganophosphorus Compounds0302 clinical medicineCoated Materials BiocompatibleCoronary thrombosisRestenosisPredictive Value of TestsRisk FactorsInternal medicineAngioplastyCoronary stentmedicineClinical endpointHumansProspective Studies030212 general & internal medicineMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryCoronary ThrombosisStentMiddle Agedmedicine.diseaseCoronary VesselsSurgeryTreatment OutcomeCardiologyNanoparticlesFemaleStentsCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Long-term beneficial effects of PTCA on segmental early relaxation in disease of the left anterior descending coronary artery.

1988

The relationship between regional left ventricular (LV) motion and global pressure relaxation of the left ventricle remains unclear. To clarify the recent concept of segmental early relaxation in coro nary artery disease, the authors in vestigated two groups of patients. In group I, all 12 patients (mean age 47±7 years) exhibited evidence of a normal heart after an extensive in vestigation. In group II, 25 patients (55±7 years) presented an isolated stenosis of the left anterior descend ing coronary artery, and they under went a hemodynamic investigation before and after (six to nine months) a durable successful percutaneous transluminal coronary angioplasty (PTCA). After all conventional …

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsHeart VentriclesHemodynamicsCoronary Disease030204 cardiovascular system & hematologyAnterior Descending Coronary Artery03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineBeneficial effectsRelaxation (psychology)business.industryHemodynamicsMiddle Agedmedicine.diseaseMyocardial ContractionSurgeryStenosismedicine.anatomical_structureVentricleCoronary vesselCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonArteryFollow-Up StudiesAngiology
researchProduct